Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
Steigende Produktionsmengen, operative Hebelwirkung und der Goldpreis könnten zusammen neue Impulse setzen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
246 Leser
Artikel bewerten:
(1)

Apollo Cancer Centres: Apollo Cancer Centre in Navi Mumbai Advances Cancer Care with 2 Successful CAR T-Cell Therapies

MUMBAI, India, Sept. 4, 2025 /PRNewswire/ -- Apollo Cancer Centre (ACC), Navi Mumbai, has successfully treated 2 patients with made-in-India CAR T-cell therapy. This ground-breaking immunotherapy used patients' own genetically modified immune cells to target and destroy cancer.

L to R - Dr Vipin Khandelwal - Consultant Paediatric Hemato Oncology & BMT Apollo Cancer Centre, Navi Mumbai, Mr Arunesh Punetha - Regional CEO Apollo Cancer Centre, Western Region, Dr Punit Jain - Consultant Hematology, Hemato Oncology & Program Coordinator BMT & CAR T-cell Therapy, Apollo Cancer Centre, Navi Mumbai, Dr Kiran Shingote - Unit Head, Apollo Cancer Centre, Navi Mumbai, Dr Ravi Shankar - Director Medical Services, Apollo Cancer Centre, Navi Mumbai, Mr Sharma - Patient relative, Dr Dipali Patil - Consultant Blood Bank

ACC has seen remarkable success with 85 Bone Marrow Transplant (BMT) procedures with a long-term success rate of over 70%, successfully treating both adult and pediatric patients, including international cases. The recent CAR T-cell procedures highlight the hospital's commitment to delivering high-quality, life-saving transplant services.

Mrs. Sharma (49 yrs) from Odisha, was fighting blood cancer called B-cell acute lymphoblastic leukemia. Her immune cells (called T-cells) were extracted & re-engineered in the ImmunoACT lab so that they express modified connectors on their surface called Chimeric Antigen Receptors (CARs) to better recognize and attack her cancer. Before receiving the infusion, she received a course of chemotherapy to help the modified cells work effectively. CAR T-cell therapy was administered to her in May 2025. She was treated for fever & low blood cell counts after the therapy. She steadily improved and was discharged after a few weeks.

The 2nd patient, Mr. Das(57 yrs) from Mumbai, was diagnosed with follicular lymphoma, a type of blood cancer that had relapsed after several treatments including chemotherapy and radiation. His own immune cells (called T-cells) were collected and modified similarly & the CAR T-cell therapy was administered in June 2025. Although he developed a fever, his condition settled with medications & he was discharged a few weeks later.

Dr Punit Jain, Sr Consultant, Hemato Oncology & Program Co-ordinator BMT & CAR T-cell Therapy, ACC, Navi Mumbai, said, "CAR T-cell therapy is rewriting what's possible for patients with blood cancers who have relapsed on conventional treatment. This therapy offers hope for a complete cure in patients with aggressive or treatment-resistant cancers. We have been successfully performing challenging high-risk bone marrow transplants & are confident of providing advanced, evidence-based treatments to patients who undergo CAR T-cell procedures."

Mr. Arunesh Punetha, Regional CEO - Western Region, Apollo Hospitals, said, "The successful CAR -T cell cases at ACC are an example of our commitment to offer advanced cancer care available in India today. We have successfully performed CAR T-cell procedures in several other ACCs & this speaks volumes about our capability to deliver patient care of the highest standard."

Visit us at - https://apollocancercentres.com/

Photo: https://mma.prnewswire.com/media/2764505/Apollo_Cancer_Centre_Team.jpg
Logo: https://mma.prnewswire.com/media/2324542/4508246/Apollo_Cancer_Centers_Logo.jpg

Apollo Cancer Centers Logo (PRNewsfoto/Apollo Cancer Centers)

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/apollo-cancer-centre-in-navi-mumbai-advances-cancer-care-with-2-successful-car-t-cell-therapies-302546481.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.